# Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)

> **NCT03532178** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 44 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline
- **DRUG:** Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;

## Key facts

- **NCT ID:** NCT03532178
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-04-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532178, "Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03532178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*